Rexahn Pharmaceuticals Inc. (RNN, Free Analysis), a clinical stage biopharmaceutical company focused on cancer and CNS diseases, was initiated with a Buy rating and $3.00 per share price target by Brean Murray ahead of the opening bell. At a significant 144% premium to the current market price, the analyst’s price target reflects a very bullish stance on the company’s future outlook.
While the stock has been beaten down in recent months by Dr. Chang Ahn’s decision to step down from CEO and a recent dilutive capital raise, the biopharmaceutical company has made considerable progress in advancing its clinical trials and Ahn has been increasing his stake in the company. As a result, this is one stock that is potentially misunderstood by the market and could be a bargain at these levels.
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM